towards improved death receptor targeted therapy for ... - TI Pharma

More documents

Recommendations

Info

Sugars in thymidine phosphorylase overexpressing cells Reference List 1. Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 2009; 29(6):903‐953. 2. Koukourakis MI, Giatromanolaki A, Kakolyris S, O'Byrne KJ, Apostolikas N, Skarlatos J et al. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non‐ small‐cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer 1998; 77(10):1696‐1703. 3. Liekens S, Bronckaers A, Perez‐Perez MJ, Balzarini J. Targeting platelet‐derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol 2007; 74(11):1555‐1567. 4. de Bruin M, Temmink OH, Hoekman K, Pinedo HM, Peters GJ. Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in health and disease. Cancer Therapy 2006;4:99‐124. 5. Hotchkiss KA, Ashton AW, Schwartz EL. Thymidine phosphorylase and 2‐deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. J Biol Chem 2003; 278(21):19272‐19279. 6. Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003; 63(2):527‐533. 7. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K et al. Identification of angiogenic activity and the cloning and expression of platelet‐derived endothelial cell growth factor. Nature 1989; 338(6216):557‐562. 8. Seeliger H, Guba M, Koehl GE, Doenecke A, Steinbauer M, Bruns CJ et al. Blockage of 2‐ deoxy‐D‐ribose‐induced angiogenesis with rapamycin counteracts a thymidine phosphorylase‐based escape mechanism available for colon cancer under 5‐fluorouracil therapy. Clin Cancer Res 2004; 10(5):1843‐1852. 9. Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A 1995; 92(4):998‐1002. 10. Sengupta S, Sellers LA, Matheson HB, Fan TP. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br J Pharmacol 2003; 139(2):219‐231. 11. de BM, Smid K, Laan AC, Noordhuis P, Fukushima M, Hoekman K et al. Rapid disappearance of deoxyribose‐1‐phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Commun 2003; 301(3):675‐679. 12. Carta MC, Mattana A, Camici M, Allegrini S, Tozzi MG, Sgarrella F. Catabolism of exogenous deoxyinosine in cultured epithelial amniotic cells. Biochim Biophys Acta 2001; 1528(2‐ 3):74‐80. 13. Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000; 60(22):6298‐6302. 14. Thornalley PJ, Wolff SP, Crabbe MJ, Stern A. The oxidation of oxyhaemoglobin by glyceraldehyde and other simple monosaccharides. Biochem J 1984; 217(3):615‐622. 15. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE‐ receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37(3):586‐600. 16. Monnier VM. Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol 1990; 45(4):B105‐B111. 17. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987; 245(1):243‐250. 18. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K et al. Angiogenic ‐ 131 ‐
Chapter 7 activity of enzymes. Nature 1994; 368(6468):198. 19. Stevenson DP, Milligan SR, Collins WP. Effects of platelet‐derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three‐dimensional model of angiogenesis. Am J Pathol 1998; 152(6):1641‐1646. 20. de BM, van CT, Van der Born K, Kruyt FA, Fukushima M, Hoekman K et al. Role of platelet‐ derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 2003; 88(6):957‐964. 21. Huck JH, Struys EA, Verhoeven NM, Jakobs C, van der Knaap MS. Profiling of pentose phosphate pathway intermediates in blood spots by tandem mass spectrometry: application to transaldolase deficiency. Clin Chem 2003; 49(8):1375‐1380. 22. de BM, Peters GJ, Oerlemans R, Assaraf YG, Masterson AJ, Adema AD et al. Sulfasalazine down‐regulates the expression of the angiogenic factors platelet‐derived endothelial cell growth factor/thymidine phosphorylase and interleukin‐8 in human monocytic‐ macrophage THP1 and U937 cells. Mol Pharmacol 2004; 66(4):1054‐1060. 23. Laurensse EJ, Pinedo HM, Peters GJ. A sensitive non‐radioactive assay for pyrimidine nucleoside phosphorylase using reversed‐phase high performance liquid chromatography. Clin Chim Acta 1988; 178(1):71‐78. 24. Wamelink MM, Struys EA, Huck JH, Roos B, van der Knaap MS, Jakobs C et al. Quantification of sugar phosphate intermediates of the pentose phosphate pathway by LC‐MS/MS: application to two new inherited defects of metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 823(1):18‐25. 25. Mathews ST, Plaisance EP, Kim T. Imaging systems for westerns: chemiluminescence vs. infrared detection. Methods Mol Biol 2009; 536:499‐513. 26. Moriwaki Y, Yamamoto T, Yamakita J, Takahashi S, Higashino K. Comparative localization of aldehyde oxidase and xanthine oxidoreductase activity in rat tissues. Histochem J 1998; 30(2):69‐74. 27. Sgarrella F, Del CA, Tozzi MG, Camici M. Deoxyribose 5‐phosphate aldolase of Bacillus cereus: purification and properties. Biochim Biophys Acta 1992; 1118(2):130‐133. 28. Cho SJ, Roman G, Yeboah F, Konishi Y. The road to advanced glycation end products: a mechanistic perspective. Curr Med Chem 2007; 14(15):1653‐1671. 29. Brown NS, Streeter EH, Jones A, Harris AL, Bicknell R. Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Br J Cancer 2005; 92(9):1696‐1701. 30. Tozzi MG, Camici M, Mascia L, Sgarrella F, Ipata PL. Pentose phosphates in nucleoside interconversion and catabolism. FEBS J 2006; 273(6):1089‐1101. 31. Pieters R, Huismans DR, Loonen AH, Peters GJ, Hahlen K, van der Does‐van den Berg et al. Adenosine deaminase and purine nucleoside phosphorylase in childhood lymphoblastic leukemia: relation with differentiation stage, in vitro drug resistance and clinical prognosis. Leukemia 1992; 6(5):375‐380. 32. van Laarhoven JP, de Bruyn CH. Purine metabolism in relation to leukemia and lymphoid cell differentiation. Leuk Res 1983; 7(4):451‐480. 33. Bardot V, Dutrillaux AM, Delattre JY, Vega F, Poisson M, Dutrillaux B et al. Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. Br J Cancer 1994; 70(2):212‐218. 34. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5‐fluorouracil. Adv Enzyme Regul 2001; 41:151‐157. 35. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 2007; 17(11):973‐987. ‐ 132 ‐
Page 2 and 3:
TRAIL-induced kinases activation an
Page 4 and 5:
TRAIL‐induced kinases activation
Page 6:
“In order to be irreplaceable one
Page 9 and 10:
‐ 8 ‐
Page 11 and 12:
Chapter 1 GENERAL INTRODUCTION Canc
Page 13 and 14:
Chapter 1 OUTLINE OF THE THESIS As
Page 15 and 16:
Chapter 1 Reference List 1. Jemal A
Page 17 and 18:
Chapter 2 ABSTRACT Tumor necrosis f
Page 19 and 20:
Chapter 2 INTRODUCTION The death li
Page 21 and 22:
Chapter 2 In preclinical studies, a
Page 23 and 24:
Chapter 2 Table 1| Summary of the k
Page 25 and 26:
Chapter 2 proliferation could be pr
Page 27 and 28:
Chapter 2 Figure 2. Canonical and n
Page 29 and 30:
Chapter 2 associated with TRAIL res
Page 31 and 32:
Chapter 2 adhesion molecules [109].
Page 33 and 34:
Chapter 2 Reference List 1. Ashkena
Page 35 and 36:
Chapter 2 37. Tolcher AW, Mita M, M
Page 37 and 38:
Chapter 2 melanoma cells from TRAIL
Page 39 and 40:
Chapter 2 and ERK pathways. Circula
Page 41 and 42:
Page 43 and 44:
Chapter 3 inhibitors and TRAIL rece
Page 45 and 46:
Chapter 3 of amplification of the t
Page 47 and 48:
Chapter 3 P38 and JNK have opposing
Page 49 and 50:
Chapter 3 Figure 2 (continued). (e)
Page 51 and 52:
Chapter 3 previously established H4
Page 53 and 54:
Chapter 3 effect on TRAIL‐induced
Page 55 and 56:
Chapter 3 induced apoptosis in H460
Page 57 and 58:
Chapter 3 Reference List 1. Jemal A
Page 59 and 60:
Chapter 3 40. Domina AM, Vrana JA,
Page 61 and 62:
Page 63 and 64:
Chapter 4 role in the activation of
Page 65 and 66:
Chapter 4 the tip with a diameter o
Page 67 and 68:
Chapter 4 RESULTS TRAIL induces a s
Page 69 and 70:
Chapter 4 vehicle control or with 5
Page 71 and 72:
Chapter 4 Non‐canonical TRAIL res
Page 73 and 74:
Chapter 4 A549‐shRIP1 cells clear
Page 75 and 76:
Chapter 4 Figure 7. Inhibition of S
Page 77 and 78:
Chapter 4 DISCUSSION The TRAIL rece
Page 79 and 80:
Chapter 4 Src‐independent mechani
Page 81 and 82: Chapter 4 variants. Cell Death Dis
Page 83 and 84: Chapter 4 ‐ 82 ‐
Page 85 and 86: Chapter 5 ABSTRACT TRAIL is an inte
Page 87 and 88: Chapter 5 targets and subsequent pr
Page 89 and 90: Chapter 5 RESULTS Synergistic activ
Page 91 and 92: Chapter 5 ng/ml TRAIL (Fig. 3B). Ap
Page 93 and 94: Chapter 5 by sub‐G1 levels in the
Page 95 and 96: Chapter 5 DISCUSSION In the present
Page 97 and 98: Chapter 5 Reference List 1. Jemal A
Page 101 and 102: Chapter 6 ABSTRACT TRAIL is a tumor
Page 103 and 104: Chapter 6 various stress stimuli [1
Page 105 and 106: Chapter 6 Subsequently, the membran
Page 107 and 108: Chapter 6 B H460 A549 Figure 1. Rep
Page 109 and 110: Chapter 6 TRAIL‐dependent cell de
Page 111 and 112: Chapter 6 B H460 A549 C Figure 4 (c
Page 113 and 114: Chapter 6 Figure 5 (continued). Mec
Page 115 and 116: Chapter 6 regulation and checkpoint
Page 117 and 118: Chapter 6 mechanism of immune evasi
Page 119 and 120: Chapter 7 ABSTRACT Thymidine phosph
Page 121 and 122: Chapter 7 Figure 1. Schematic overv
Page 123 and 124: Chapter 7 that was measured before
Page 125 and 126: Chapter 7 RESULTS TdR conversion to
Page 127 and 128: Chapter 7 dR is secreted from the c
Page 129 and 130: Chapter 7 Figure 4. Accumulation of
Page 131: Chapter 7 angiogenic properties. Ho
Page 137 and 138: Chapter 8 SUMMARIZING DISCUSSION AN
Page 139 and 140: Chapter 8 Recently, various differe
Page 141 and 142: Chapter 8 in phase II clinical tria
Page 143 and 144: Chapter 8 Reference List 1. Herbst
Page 147 and 148: Chapter 9 NEDERLANDSE SAMENVATTING
Page 149 and 150: Chapter 9 waargenomen. Het gebruik
Page 151 and 152: Chapter 9 CONCLUSIE Het activeren v
Page 153 and 154: zelfs na werktijden (lees 23:45) ko
Page 155 and 156: Verder wil ik ook dr. Eric Ronken b
show all

towards improved death receptor targeted therapy for ... - TI Pharma

Create successful ePaper yourself

Delete template?

Save as template?